Benitec Biopharma(BNTC) - 2024 Q4 - Annual Results

Financial Performance - Total revenues for the year ended June 30, 2024, were $0 million, a decrease from $75,000 in licensing revenues for the year ended June 30, 2023[8] - Total expenses for the year ended June 30, 2024, were $22.5 million, compared to $19.2 million for the year ended June 30, 2023, with R&D expenses increasing to $15.6 million from $12.8 million[8] - The net loss attributable to shareholders for the year ended June 30, 2024, was $22.4 million, or $5.51 per share, compared to a net loss of $19.6 million, or $14.12 per share for the previous year[9] - Total revenues for the year ended June 30, 2024, were $75,000, a decrease compared to the previous year[17] - The net loss for the year was $21,751,000, compared to a net loss of $19,562,000 in the previous year, representing an increase in loss of approximately 11.1%[17] - The net loss attributable to common shareholders was $22,370,000, compared to $19,562,000, showing an increase of about 14.2%[17] - Basic and diluted net loss per share was $(6), compared to $(14) in the previous year, indicating a significant improvement in loss per share[17] - Total comprehensive loss for the year was $(21,813,000), compared to $(19,147,000) in the previous year, an increase of about 13.9%[17] Cash and Assets - The company closed an oversubscribed private placement financing of $40.0 million on April 22, 2024, extending its cash runway through 2025[1] - As of June 30, 2024, the company had $50.9 million in cash and cash equivalents, a significant increase from $2.5 million as of June 30, 2023[9] - The company’s total assets increased to $52.2 million as of June 30, 2024, compared to $4.5 million as of June 30, 2023[15] - Total stockholders' equity rose to $47.2 million as of June 30, 2024, compared to $202,000 in the previous year[16] Research and Development - The first subject in the BB-301 Phase 1b/2a clinical study showed meaningful improvements in swallowing efficiency at both 90-day and 180-day assessments[4][5] - The second subject was dosed with BB-301 in February 2024, and the third subject is expected to be dosed in Q4 2024[6] - No serious adverse events have been reported for the two subjects that received the low-dose of BB-301, with only transient Grade 2 GERD observed[6] - Research and development expenses increased to $15,609,000 from $12,774,000, reflecting a growth of approximately 22.8%[17] Operating Expenses - Total operating expenses rose to $22,490,000, up from $19,156,000, indicating an increase of about 12.1%[17] - Other comprehensive loss included an unrealized foreign currency translation loss of $(62,000) compared to a gain of $415,000 in the previous year[17] - Interest income increased to $904,000 from a net expense of $(33,000), indicating a significant turnaround in financial performance[17]